Pharming Group reports second quarter and first half 2023 financial results : vimarsana.com

RUCONEST® business performed strongly in 2Q 2023; continue to anticipate low single digit annual revenue growth Strong start to U.S. Joenja® launch during 2Q...

Related Keywords

Canada , London , City Of , United Kingdom , Japan , Australia , Netherlands , United States , Israel , Amsterdam , Noord Holland , America , Australian , Dutch , Canadian , Japanese , Israeli , Barbara Yanni , Paul Sekhri , Alexander Breidenbach , Heather Robertson , Michael Levitan , Deborah Jorn , Richard Peters , Leonard Kruimer , Foster Mitchell Alex Shaw , Mark Pykett , Steven Baert , Access Program , Linkedin , International Accounting Standards Board , Vp Investor Relations Corporate Communications , Therapeutic Goods Administration , Company Euronext Amsterdam , European Medicines Agency , Patient Program , Drug Submission To Health Canada , Expert Group , Exchange Commission , Drug Administration , Novartis , Committee For Human Medicinal Products , Israeli Ministry Of Health , Pharming Group , Regulatory Agency , International Accounting Standard , Prnewswire Pharming Groupnv , Nasdaq , Investor Relations Corporate Communications , Ministry Of Health , Japan Pharmaceuticals , European Commission Decision Reliance Procedure , International Financial Reporting Standards , Lifespring Life Sciences Communication , Devices Agency , Euronext Amsterdam , Executive Officer , Sijmen De Vries , Expanded Access Program , Open Label Extension , Priority Review , Rare Pediatric Disease Priority Review Voucher , Annual Report , Human Medicinal Products , Marketing Authorisation Application , Ad Hoc Expert Group , Scientific Advisory Groups , Orphan Drug Designation , Medical Devices Agency , New Drug Submission , Health Canada , Product Registration Application , Israeli Ministry , Pediatric Investigational Plan , Investigational New Drug , Chief Business , Non Executive Director , Extraordinary General Meeting , Chief Business Officer , Chief Development Officer , Marketing Authorisation , Conference Call Dial In Details , Investor Relations , Corporate Communications , Spring Life Sciences Communication , North America , Middle East , Dutch Financial Supervision Act , Executive Director , Chief Executive , Consolidated Interim Financial Statements , Dutch Civil Code , Pivot Park , Orchard Therapeutics , Executive Committee , Pharming Groupnv ,